昭衍新药 (603127)

Joinn Laboratories (China) Co., Ltd.

ASH

Tags

Contract Research Organization (CXO)SSE 380 IndexSpecialized-Sophisticated-Distinctive-Innovative EnterprisesImmunotherapyInnovative DrugsMedical ServicesPharmaceuticals and HealthcareContains H-SharesBuyback PlansPlanned Reduction of HoldingsBiological VaccinesResearch and Experimental DevelopmentNew Social Security Fund HoldingsMargin Trading and Securities Lending

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 74947.73
  • Circulating A-Shares(W): 63048.21
  • Earnings Per Share(RMB): 0.1100
  • Net Assets Per Share(RMB): 10.8351
  • Operating Revenue(W RMB): 98496.15
  • Total Profit(W RMB): 9962.54
  • **Net Profit Attributable to Parent(W RMB) **: 8070.61
  • Net Profit Growth Rate(%): 214.79
  • Weighted Return on Equity(%): 1.0000
  • Operating Cash Flow Per Share(RMB): 0.3550
  • Undistributed Profit Per Share(RMB): 2.8731
  • Capital Reserve Per Share(RMB): 6.9884

2. Main Business

The main business covers:

  • Drug non-clinical safety evaluation services
  • Pre-clinical research services for drugs
  • Sales of laboratory animals and related products

3. Company Basic Information

  • Company Name: Beijing Joinn Laboratories Co., Ltd.
  • Listing Date: 2017-08-25
  • Industry: Pharmaceuticals & Healthcare - Medical Services
  • Address: No. 5A Rongjing East Street, Beijing Economic-Technological Development Area, Beijing
  • Website: https://www.joinnlabs.com/
  • Company Profile: The company was established through the overall transformation of Beijing Joinn Laboratories Co., Ltd. Approved by the shareholders' meeting of the former Joinn Co., Ltd. on November 20, 2012, all original shareholders of Joinn Co., Ltd. acted as promoters, converting the audited net assets of RMB 121,038,060.33 as of June 30, 2012 into RMB 61.30 million in share capital, with the remaining portion credited to capital reserve. Joinn Co., Ltd. was wholly transformed into a joint stock company, and the company name was changed to Beijing Joinn Laboratories Co., Ltd. On December 10, 2012, ShineWing Certified Public Accountants (Special General Partnership) reviewed the capital contribution for the transformation into a joint stock company and issued the "XYZH/2012A9007-1" Capital Verification Report. On December 26, 2012, the company completed the industrial and commercial registration change with the Beijing Administration for Industry and Commerce and obtained the Business License with registration number "110106002952913".

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Huabao CSI Medical ETF Fund 1248.38 1.98
2 GF Small Cap Growth Mixed Securities Investment Fund (LOF) Class A Fund 1028.32 1.63
3 GF Innovation Upgrade Flexible Allocation Mixed Securities Investment Fund Fund 921.40 1.46
4 GF Fund Management Co., Ltd. - National Social Security Fund Combination 420 Social Security Fund 670.36 1.06
5 Xingquan Selected Mixed Securities Investment Fund Fund 188.65 0.30
6 ChinaAMC Stable Prosperity Flexible Allocation Mixed Securities Investment Fund Fund 167.68 0.27
7 Tianhong Healthcare Mixed Securities Investment Fund Class A Fund 116.95 0.19
8 Rongtong Healthcare Industry Mixed Securities Investment Fund Class A Fund 93.83 0.15
9 ChinaAMC Industry Selection Mixed Securities Investment Fund (LOF) Fund 79.49 0.13
10 Huashang Twin Engines Leading Mixed Securities Investment Fund Fund 59.40 0.09

5. Concept Sectors

  • H-Share
  • Biological Vaccines
  • Immunotherapy
  • CXO Concept
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • Share Repurchase Plan
  • Yesterday's Volatility
  • Proposed Reduction
  • New Social Security Fund Holdings
  • Specialized, Refined, Unique, and New Enterprises
  • SSE 380 Index

Remarks

  • Data update date: 2025-09-30
  • Data source: Public Market Information